U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H28N2O
Molecular Weight 348.4812
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BL-1021 FREE BASE

SMILES

CN(CCC=C1C2=CC=CC=C2CCC3=CC=CC=C13)C(=O)CCCN

InChI

InChIKey=DOIAVGICIXNFIH-UHFFFAOYSA-N
InChI=1S/C23H28N2O/c1-25(23(26)13-6-16-24)17-7-12-22-20-10-4-2-8-18(20)14-15-19-9-3-5-11-21(19)22/h2-5,8-12H,6-7,13-17,24H2,1H3

HIDE SMILES / InChI
Molecular Formula C23H28N2O
Molecular Weight 348.4812
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

BL-1021 was developed by BioLineRx Ltd. for the treatment of neuropathic pain or pain that results from damage to nerve fibers. The drug has completed phase I clinical trials, however further information is not available.

Originator

Approval Year

Unknown
149124

Sample Use Guides

In Vivo Use Guide
a single administration of BL-1021 at doses between 10mg and 80mg in healthy volunteers.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Mon Mar 31 23:03:10 GMT 2025
Edited
by admin
on Mon Mar 31 23:03:10 GMT 2025
Record UNII
16226S07N3
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BL-1021 FREE BASE
Common Name English
BUTANAMIDE, 4-AMINO-N-(3-(10,11-DIHYDRO-5H-DIBENZO(A,D)CYCLOHEPTEN-5-YLIDENE)PROPYL)-N-METHYL-
Preferred Name English
Code System Code Type Description
CAS
1002404-34-3
Created by admin on Mon Mar 31 23:03:10 GMT 2025 , Edited by admin on Mon Mar 31 23:03:10 GMT 2025
PRIMARY
PUBCHEM
24898307
Created by admin on Mon Mar 31 23:03:10 GMT 2025 , Edited by admin on Mon Mar 31 23:03:10 GMT 2025
PRIMARY
EPA CompTox
DTXSID60647859
Created by admin on Mon Mar 31 23:03:10 GMT 2025 , Edited by admin on Mon Mar 31 23:03:10 GMT 2025
PRIMARY
FDA UNII
16226S07N3
Created by admin on Mon Mar 31 23:03:10 GMT 2025 , Edited by admin on Mon Mar 31 23:03:10 GMT 2025
PRIMARY
Related Record Type Details
Structure of BL-1021
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of BL-1021 FREE BASE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966